Showing results (181-190 of 196) with videos related to
Sort By:
Pageof 20
Transplantation|June 23, 2025
Risk Factors for Solid Organ Graft Failure and Death in Hematopoietic Cell Transplant Recipients Undergoing Solid Organ Transplantation: A Retrospective Center for International Blood and Marrow Transplant Research and Organ Procurement and Transplantation Network StudyMeera Gupta, Michelle L Schoettler, Ruta Brazauskas, et al.Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 16, 2014
Long-term survival and late effects among one-year survivors of second allogeneic hematopoietic cell transplantation for relapsed acute leukemia and myelodysplastic syndromesChristine N Duncan, Navneet S Majhail, Ruta Brazauskas, et al.The New England Journal of Medicine|May 7, 2025
Enhanced CAR T-Cell Therapy for Lymphoma after Previous FailureJakub Svoboda, Daniel J Landsburg, James Gerson, et al.Nature|February 3, 2022
Decade-long leukaemia remissions with persistence of CD4+ CAR T cellsJ Joseph Melenhorst, Gregory M Chen, Meng Wang, et al.Nature Medicine|May 2, 2018
Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemiaJoseph A Fraietta, Simon F Lacey, Elena J Orlando, et al.The Lancet. Haematology|March 3, 2019
Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203)Javier Bolaños-Meade, Ran Reshef, Raphael Fraser, et al.Nature Medicine|January 24, 2024
T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapyGuido Ghilardi, Joseph A Fraietta, James N Gerson, et al.The Journal of Clinical Investigation|August 16, 2021
BET bromodomain protein inhibition reverses chimeric antigen receptor extinction and reinvigorates exhausted T cells in chronic lymphocytic leukemiaWeimin Kong, Alexander Dimitri, Wenliang Wang, et al.Nature|June 1, 2018
Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cellsJoseph A Fraietta, Christopher L Nobles, Morgan A Sammons, et al.Nature Biomedical Engineering|March 10, 2026
Predictive biomarkers of response to chimeric antigen receptor (CAR) T-cell therapy for pan-haematologic cancerGregory M Chen, Ankita Jain, David T Gering, et al.Pageof 20